Dr. Kamal Kant Sahu

DM Clinical Hematology/BMT (PGI, Chandigarh), Hematology/Oncology Fellow at Huntsman Cancer Institute, SLC, Utah, United States

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in #ASCODailyNews 👉SPOP mutation as predictive biomarker for Rx selection for ARSIs in mHSPC #prostatecancer & potential use in “de-escalation”. Excellent article by our star trainee @ggebraelmd 👇 & @Huntsman_GU team @umangtalking @nsayeghmd Cc’ing: @PCF_Science @urotoday @OncoAlert @ZEROCancer and investigators with de-escalation trials: @AtishChoudhury @AzadOncology @scserendipity1 @CaPsurvivorship @TiansterZhang @DrKarieRuncie @DRathkopf @ChrisSweens1

[𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD]

⚡️Tanya Jindal and I talk about her UNITE study w/Dr. Koshkin.

✅Favorite moments of @ASCO #GU23 include talking to rising ⭐️s in GU about their research and the impact of their outstanding mentors.

@koshkin85 @PGrivasMDPhD @PBarataMD @maughanonc

@OncoAlert

[𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD]

⭐️BEST parts of @ASCO #GU23

1️⃣Catching up with friends
2️⃣Learning new ideas
3️⃣FUN conversations
4️⃣Making new friends.

@MehtaScribe @neerajaiims @montypal @cparker399 @AmandaNizamMD @PGrivasMDPhD @DRBakaloudiMD @AJangMD @ZakhariaYousef @rohitjainMD @koshkin85 @Tanjin097

[𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @CParkMD]

⚡️Does a PARP inhibitor in men w/tx naïve high-risk nmHSPC allow delay of ADT and onset of metastasis?

✅Dr. Sahu discusses his promising study and spoke highly of his mentors

@maughanonc @neerajaiims @sahuonc @ASCO #GU23
👇
https://t.co/xPGT84lnMT

[Nat Lester-Coll, MD @DrLesterColl]

#GU23 in this observational study of 1st line tx (IO v TKI) in #mRCC, interesting to see from a #radonc perspective

📈SRS 📉WBRT

SRS & resection associated with⬆️OS - likely better prognosis at baseline, but underscores importance of aggressive local tx in these pts
@OncoAlert

[Karine Tawagi MD @DrKarineTawagi]

We need to keep encouraging #HPVvaccination to continue to see trends in the prevention of HPV-associated cancers: cervical, oropharyngeal, anorectal & penile cancers #GU23 by @MaartenAlbersen:
🌀routine 💉@ 9-12yo
🌀catch-up 💉@ 13-26yo
🌀shared-decision 💉 @ 27-45yo

[Therapeutic Advances in Urology @TA_Urology]

Don't leave #GU23 without visiting this interesting poster authored by our Editorial Board Member @fsabino_onco and this incredible team! ⬇️ 🇧🇷

[Shuchi Gulati MD @ShuchiGulati]

#GU23
Important presentation on much needed data #DrTakemura presenting @IMDConline data on RCC patients with brain Mets:
- incidence ~7.9% at 1L rx
- IO based therapies important
- need multi-d approach for brain-directed therapies in combination!

[Shuchi Gulati MD @ShuchiGulati]

#GU23 @ASCO
Tour de force by none other that @TiansterZhang! An elegant handling of a complex topic. Also a call for action to work toward biomarkers of immune resistance!

[Karine Tawagi MD @DrKarineTawagi]

Updates in non-clear-cell RCC by Dr. McGregor #GU23
🌀PAPMET: papillary RCC OS cabo>sunitinib
➡️MET: savolitinib trials ongoing
✳️HRLCC: Bev+erlotinib, trial adding atezo
🌀IO/VEGF generally > IO alone
➡️ many advances, histology directed therapy ultimate goal, trials ongoing

[Karine Tawagi MD @DrKarineTawagi]

Very high yield overview of adjuvant IO in #RCC by @MattZibelman:
❓diff btwn PD1 or PDL1? KN564 pembro (only FDA approved)
🛑 no benefit in IMmotion010 (PDL1 atezo), CM-914 (ipi/nivo) and PROSPER (periop nivo)
➡️ What matters to clinicians/pts? OS, prioritize most at risk
#GU23

[Sumanta K. Pal, MD, FASCO @montypal]

To ALL @SWOG colleagues (not just my @ASCO #GU23 network!): @lissmike & I will be hosting a #microbiome symposium at the #SWOG Spring Mtg. Keynote from @BertrandRouty w talks from @LauraBukavinaMD @NazliDizman @nadim_ajami. Want to hear concepts from #lungcancer, #melanoma, (1/2)

[Tom Powles @tompowles1]

Cabopoint prospectively explores cabo in ICI refactory disease. RR of 30% post ipi/nivo and 25% post VEGF/ICI therapy show sequencing these agents is of benifit. It strengthens the data for Cabo in this setting which joins axi and pazo with prospect data in this setting. #GU23

[Shuchi Gulati MD @ShuchiGulati]

#GU23
Terrific talk from @tompowles1 on subgroups from #COSMIC313
- PFS benefit of triplet maintained
HR 0.74 in all Pts and 0.68 in intermediate
Follow-up for OS ongoing

[Shuchi Gulati MD @ShuchiGulati]

#GU23
#Dr.Atkins presents the HCRN GU16-260-Cohort A:
-NIVO monotherapy with salvage NIVO/PI in non-responders is active with TFS and TRAE-free TFS
- particularly noted in pts with favorable risk disease

[Brian Ramnaraign, MD @RamnaraignMD]

Updated COSMIC 313 results presented by @tompowles1 @ASCO #GU23

[Maite Bourlon @BourlonMaite]

Thanks @ASCO for the opportunity! 🇲🇽👩🏻‍⚕️ 💙

Best of journals in Medical Oncology for RCC #kidneycancer @IKCCorg

🔸Triple therapy in mRCC
🔹TKI & IO cabo+nivo one of the highest responses in non-clear cell
🔸Pembro continues to have DFS. Atezolizumab & Ipi/Nivo no DFS or OS

[Li Haoran, MD, PhD @lihaoran]

#GU23 @ASCO Abs #726: Clinical characteristics, tumor genomic and transcriptomic profiles of pts with #mRCC who developed VTE: hormone metabolic, organic acid transport, extracellular matrix pathways associated with elevated risk of VTE. #meritaward https://t.co/999ucimyAd

[Maite Bourlon @BourlonMaite]

iPARPs in HRR negative population read our article!!! 👩🏻‍⚕️👨‍⚕️👩🏻‍⚕️@ASCO #ASCOGU23 🇲🇽🇺🇸🇪🇸

PARPi in Patients With HRR-Negative mCRPC: Why Would These Therapies Work in the Absence of a Mutation?

🔸DNA proficient tumor cells tx w iPARP with hormonal agents, radioligands & IO (figures)

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

The legend and the man. @DrChoueiri presents #Checkmate9ER biomarkers — gene expression profiling, #PDL1, #CD8, #MET associations w PFS outcomes. @ASCO #GU23 @OncoAlert